Literature DB >> 19560226

Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.

Paolo Gisondi1, Giovanni Targher, Giacomo Zoppini, Giampiero Girolomoni.   

Abstract

BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD) and chronic plaque psoriasis are both associated with metabolic syndrome and increased risk of incident cardiovascular disease. We assessed the frequency and characteristics of NAFLD in patients with chronic plaque psoriasis.
METHODS: One hundred and thirty consecutive patients with chronic plaque psoriasis and 260 apparently healthy controls matched for age, sex and body mass index were enrolled. NAFLD was diagnosed by abdominal ultrasound after excluding other secondary causes of chronic liver disease.
RESULTS: The frequency of NAFLD was remarkably greater in psoriasis patients than in controls (47% vs. 28%; p<0.0001). Patients with psoriasis and NAFLD (n=61) were more likely to have metabolic syndrome and had higher serum C-reactive protein concentrations and greater severity of psoriasis according to the Psoriasis Area and Severity Index (PASI) score (14.2+/-12.6 vs. 9.6+/-7.4; p<0.01) than those with psoriasis alone (n=69). In a subgroup of psoriasis patients (n=43), those with NAFLD (n=21) also had significantly higher serum interleukin-6 and lower serum adiponectin levels. Notably, in multivariate regression analysis, NAFLD was associated with higher PASI score independently of age, gender, body mass index, psoriasis duration, and alcohol consumption.
CONCLUSIONS: NAFLD is frequent in patients with chronic plaque psoriasis - affecting up to nearly half of these patients - and is strongly associated with psoriasis severity. Early recognition of NAFLD by radiological imaging tests in this group of patients is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19560226     DOI: 10.1016/j.jhep.2009.04.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  47 in total

Review 1.  Non-alcoholic fatty liver disease and psoriasis: So far, so near.

Authors:  Giulia Ganzetti; Anna Campanati; Annamaria Offidani
Journal:  World J Hepatol       Date:  2015-03-27

2.  Pediatric Psoriasis Comorbidity Screening Guidelines.

Authors:  Emily Osier; Audrey S Wang; Megha M Tollefson; Kelly M Cordoro; Stephen R Daniels; Andrew Eichenfield; Joel M Gelfand; Alice B Gottlieb; Alexa B Kimball; Mark Lebwohl; Nehal N Mehta; Amy S Paller; Jeffrey B Schwimmer; Dennis M Styne; Abby S Van Voorhees; Wynnis L Tom; Lawrence F Eichenfield
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

3.  A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis.

Authors:  Olabola Awosika; Misty G Eleryan; Monica Rengifo-Pardo; Lindsay Doherty; Lisa W Martin; Alison Ehrlich
Journal:  J Clin Aesthet Dermatol       Date:  2018-06-01

Review 4.  Nonalcoholic Fatty liver disease and psoriasis: what a dermatologist needs to know.

Authors:  Ronald Prussick; Lisa Prussick; Dillon Nussbaum
Journal:  J Clin Aesthet Dermatol       Date:  2015-03

5.  A subpopulation of CD163-positive macrophages is classically activated in psoriasis.

Authors:  Judilyn Fuentes-Duculan; Mayte Suárez-Fariñas; Lisa C Zaba; Kristine E Nograles; Katherine C Pierson; Hiroshi Mitsui; Cara A Pensabene; Julia Kzhyshkowska; James G Krueger; Michelle A Lowes
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

6.  Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.

Authors:  Augusta Ortolan; Mariagrazia Lorenzin; Giulia Tadiotto; Francesco Paolo Russo; Francesca Oliviero; Mara Felicetti; Renata D'Incà; Marta Favero; Stefano Piaserico; Andrea Doria; Roberta Ramonda
Journal:  Clin Rheumatol       Date:  2019-06-28       Impact factor: 2.980

7.  The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.

Authors:  A Campanati; G Ganzetti; A Di Sario; A Damiani; L Sandroni; L Rosa; A Benedetti; A Offidani
Journal:  J Gastroenterol       Date:  2012-10-13       Impact factor: 7.527

Review 8.  Does treatment of psoriasis reduce the risk of cardiovascular disease?

Authors:  Sarah Churton; Liza Brown; Thuzar M Shin; Neil J Korman
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

9.  Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.

Authors:  Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-10       Impact factor: 10.282

10.  Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study.

Authors:  Alexis Ogdie; Sungat K Grewal; Megan H Noe; Daniel B Shin; Junko Takeshita; Zelma C Chiesa Fuxench; Rotonya M Carr; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2017-11-02       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.